Aimmune Therapeutics Inc. (NASDAQ:AIMT)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $11.13, but opened at $11.16. Aimmune Therapeutics shares last traded at $11.59, with a volume of 66,126 shares trading hands.

Several equities analysts recently issued reports on the stock. Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a report on Friday, May 20th. Bank of America Corp. reissued a “buy” rating on shares of Aimmune Therapeutics in a report on Monday, May 16th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $38.00 target price on shares of Aimmune Therapeutics in a research note on Tuesday, May 17th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a research note on Monday, May 16th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Aimmune Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $33.40.

The firm has a 50-day moving average price of $12.06 and a 200 day moving average price of $14.18. The company’s market capitalization is $481.19 million.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.03. On average, analysts anticipate that Aimmune Therapeutics Inc. will post ($1.70) EPS for the current year.

In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the company’s stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $15.23, for a total value of $3,655,200.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

A hedge fund recently raised its stake in Aimmune Therapeutics stock. Aisling Capital LLC raised its stake in shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) by 6.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,990,000 shares of the company’s stock after buying an additional 170,000 shares during the period. Aimmune Therapeutics makes up 9.5% of Aisling Capital LLC’s holdings, making the stock its 4th largest position. Aisling Capital LLC owned about 7.08% of Aimmune Therapeutics worth $55,166,000 at the end of the most recent quarter.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.